NVO - Key debate themes for the industries in 2024 - MS
2023-12-27 13:55:07 ET
More on Eli Lilly:
- Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade)
- Eli Lilly: Long Path To A Trillion
- Bubble Warning: Unrealistic Growth Priced In And Multiple Risk Factors For Eli Lilly
- FDA’s new drug approvals for 2023 rise 51% from last year
- Eli Lilly completes $1.4B purchase of Point Biopharma
For further details see:
Key debate themes for the industries in 2024 - MS